What did BrainChip report?

• Revenue of US$1,222,745, up 19% from 1H 2025
• Net loss after tax of US$12,015,897 (1H 2025: US$9,360,251)
• Operating expenses increased 33% to US$13,647,140
• Cash and cash equivalents of US$20,304,971 as at 30 June 2026
• No interim dividend declared

What else do investors need to know?

BrainChip achieved a significant operational milestone by shipping the first production batch of 2,000 AKD1500 neuromorphic processors, marking the transition from pre-production to commercial-scale manufacturing. The company is also developing AKD1500-based hardware platforms to support faster customer adoption.

During the half, BrainChip signed new intellectual property (IP) licensing deals with EDGEAI and ASICLAND, opening up new streams for potential licensing and royalty revenue. The ecosystem expanded through a new partnership with MicroIP, while dedicated product platforms for defence, industrial AI, and signal analytics were advanced.

Costs rose as BrainChip invested in R&D, commercialisation efforts, and supporting its next-generation AKD2500 chip—still tracking for a late-2026 development milestone. The company's financing facility with LDA Capital concluded during the period, with all obligations substantially settled.

What's next for BrainChip?

BrainChip is focused on broadening commercial deployment of its Akida neuromorphic technology across defence, industrial, and edge AI markets. The company expects further product shipments, ecosystem partnerships, and customer integrations in the coming months.

Development of the AKD2500 chip and BrainChip's Generative AI program remain key priorities, with internal demonstrations of its GenAI platform targeted by year-end. Management says groundwork is being laid for increased commercial and licensing revenue ahead of anticipated larger-scale customer uptake.

BrainChip share price snapshot

Over the past 12 months, BrainChip shares have declined 33%, trailing the All Ordinaries Index (ASX: XAO), which has risen 1% over the same period.

View Original Announcement

The post BrainChip shares: Half-year results show revenue up, loss widens appeared first on The Motley Fool Australia.

What did BrainChip report?

• Quarter-end cash balance: US$20.3 million (down from US$25.3 million last quarter)
• First production batch of 2,000 AKD1500 chips received, kicking off commercial manufacturing
• Commercial delivery of Akida 2.0 IP design assets to EDGEAI
• Net operating cash outflow: US$4.7 million for the quarter (improved from US$5.3 million last quarter)
• Expiration of LDA Capital Put Option Facility, with A$1.0 million Failure Fee settled

What else do investors need to know?

BrainChip shifted from pre-production to commercial-scale manufacturing, with the first AKD1500 units ready for customer deployment across defence, industrial, and edge AI markets. Further shipments are due in Q3 as production scales toward a run of about 60,000 chips, though initial yields were a bit lower than expected.

The company saw the expiry of its Put Option Agreement with LDA Capital. The associated A$1.0 million contractual obligation was settled by LDA selling collateral shares, resolving outstanding arrangements. BrainChip expects to update the market once remaining collateral shares are disposed of and net funds remitted.

On the technology front, BrainChip is investing in a range of hardware form factors—like M.2 and PCIe accelerator cards, Raspberry Pi boards, and reference platforms—to accelerate customer adoption of its AKD1500 chip. The AKD2500 project and a Generative AI platform also remain on track.

What's next for BrainChip Holdings?

BrainChip is set to dispatch additional AKD1500 units through the next quarter, supporting customer pilots and expanding commercial reach. Management expects these ready-to-use hardware platforms to lower integration barriers, shorten sales cycles, and build recurring revenue from silicon sales and IP licensing.

Longer term, BrainChip is advancing its AKD2500 and Generative AI projects, while expanding its ecosystem of software partners and licensed technology customers. The company aims to capture growing demand for low-power, edge-based artificial intelligence solutions.

BrainChip Holdings share price snapshot

Over the past 12 months, BrainChip shares have declined 45%, trailing the All Ordinaries Index (ASX: XAO), which is flat over the same period.

View Original Announcement

The post BrainChip posts Q2 cash, chips hit commercial production appeared first on The Motley Fool Australia.

But not every beaten-down ASX share is a bargain. Sometimes a stock is cheap because the business is getting worse, earnings are under pressure, or the market has finally stopped believing an over-optimistic story.

So how can investors tell the difference?

Start with the reason for the fall

The first step is to understand why the share price has dropped.

A high-quality company can fall because of short-term market fear, weaker sentiment, broker downgrades, or concerns that may prove less damaging than investors first thought.

ResMed Inc (ASX: RMD) is a good example of a company that has been sold down at times because of worries about competition, margins, and weight-loss drugs. This is despite it continuing to record strong earnings growth year after year.

That is very different from a company falling because of repeated earnings downgrades, weak cash flow, rising debt, governance problems, or a business model that is not delivering.

A share price fall is not enough information by itself. The reason behind the fall is what needs the most attention.

Check whether earnings can recover

A cheap-looking ASX share needs a believable path back to better profits.

Investors can ask whether revenue is still growing, whether margins can improve, whether costs are under control, and whether management has a realistic plan.

CSL Ltd (ASX: CSL) shows why this is so important. After a sharp share price fall, the key issue is not simply whether the healthcare giant looks cheaper than it used to. Investors need to assess whether its plasma, vaccines, and Vifor businesses can rebuild momentum after a difficult period.

A value trap is more dangerous because earnings keep sliding while the share price keeps looking cheaper on old numbers.

That is why relying only on a low price-to-earnings ratio can be risky. A stock trading on 10 times earnings is not cheap if those earnings are about to fall sharply.

Look at the balance sheet

Debt can turn a difficult period into a serious problem.

A company with a strong balance sheet has more options. It can keep investing, absorb weaker conditions, avoid emergency capital raisings, and wait for the cycle to improve.

A heavily indebted company has less room to make mistakes.

Higher interest costs can eat into profits, lenders may become more demanding, and shareholders can be diluted if the company needs fresh equity at a weak share price.

That is particularly important with smaller speculative shares. Brainchip Holdings Ltd (ASX: BRN), for example, has regularly attracted attention because of its technology story, but investors also need to consider revenue, cash burn, and dilution when judging whether a lower share price is really a bargain. In Brainchip's case, investors buying the dip have consistently experienced further weakness.

Separate sentiment from substance

Markets can become too negative. A company may still have valuable assets, loyal customers, strong brands, useful technology, or a leading market position even when the share price is under pressure.

That is often where long-term investors can find opportunity. 

WiseTech Global Ltd (ASX: WTC) is an interesting case because the business still has high-quality logistics software, but governance concerns and leadership uncertainty have weighed heavily on confidence. That shows how a damaged share price can sometimes reflect issues outside the core product.

The key is separating a damaged share price from a damaged business.

If the market is worried but the company's competitive position remains strong, the selloff may eventually prove excessive.

If customers are leaving, margins are shrinking, debt is rising, and management keeps missing guidance, the lower share price may be telling the truth.

Be patient

Investors do not need to decide immediately. A watchlist can be useful because it allows time to follow company updates, compare management promises with results, and see whether the investment case is improving.

Some fallen ASX shares will recover strongly. Others will keep disappointing.

The best bargains usually come from quality businesses facing temporary pressure, not weak businesses wearing a cheaper price tag.

The post How to tell if an ASX share is cheap or a value trap appeared first on The Motley Fool Australia.

Should you buy more, keep holding, or cut your losses?

The answer depends on what has changed. A share price fall can create a genuine opportunity when the market has become too pessimistic about a strong business.

It can also be a warning sign when the company keeps missing expectations, burning cash, or relying on investors to fund the story.

Here is a simple way to think through it.

Start with the reason for the fall

The first step is to understand why the share price has declined.

Some falls are driven by market-wide pressure. Rising interest rates, recession fears, sector selloffs, and valuation resets can drag down good companies along with weaker ones.

Other falls are more company-specific. Earnings downgrades, weak sales, management changes, balance sheet stress, or repeated execution problems can point to deeper issues.

This distinction is important. A quality company caught in a broad selloff can become more attractive as the price falls. A company with a deteriorating business model may become riskier with every decline.

Check whether the business still has substance

The next question is whether the company still has something valuable underneath the falling share price.

This could be a strong brand, essential product, loyal customer base, high switching costs, valuable infrastructure, recurring revenue, or exposure to a market with long-term demand.

ResMed Inc (ASX: RMD) is a useful example of a fallen share that could still justify a positive view.

Its share price has been under pressure, but the company remains a global leader in sleep apnoea treatment and connected respiratory care. The long-term need for better diagnosis, treatment, masks, devices, and patient support has not disappeared. That gives investors a real business to assess, rather than simply a share price chart to react to.

When a company still has scale, earnings power, and a large market opportunity, buying on weakness can make sense for patient investors.

Look at the numbers, not just the story

Shares often come with persuasive narratives.

Management may talk about technology, innovation, disruption, and large future markets. Those claims become far more useful when they are supported by revenue, cash flow, customer adoption, and improving economics.

This is where Brainchip Holdings Ltd (ASX: BRN) looks very different.

Its shares are down 16% over the past 12 months and 70% over the past five years. It has consistently been making new 52-week lows since 2022, while the company continues to talk up its technology but has delivered next to no revenue and significant dilution from share issues.

That is a warning for investors. A share can keep looking cheaper as the price falls, while the underlying business fails to build the revenue base needed to support the valuation.

Decide what would change your mind

Investors should know what they need to see before buying more or continuing to hold.

For a high-quality ASX share, that might be evidence that margins are stabilising, demand remains strong, new products are gaining traction, or management is executing well.

For a speculative company, the bar should be higher. Investors may want to see meaningful revenue, commercial contracts, less reliance on capital raisings, and proof that customers are willing to pay for the technology.

Buy, hold, or sell?

Buying more can make sense when the business remains strong, the balance sheet is sound, and the market appears too focused on short-term concerns.

Holding can be sensible when the company is still attractive but there is not enough evidence yet to increase exposure.

Selling becomes easier to justify when the company's problems are worsening, the story is not translating into financial progress, or shareholders are being diluted while waiting for promised growth.

The best decision is rarely based on the share price fall alone. It likely comes from comparing today's price with the quality of the business, the strength of the balance sheet, the evidence in the numbers, and the probability that the company can create value over the years ahead.

The post How to decide whether to buy, hold, or sell a fallen ASX share appeared first on The Motley Fool Australia.

At the time of writing, the BrainChip share price is up 6.45% to 16 cents.

Adding in today's increase, the stock has now climbed about 13% over the past month.

But while this shows some momentum, it remains down roughly 35% over the past year on the back of a weakened tech sector.

Here's what the company just reported to the market.

New licensing deal opens another pathway

In its release, BrainChip announced it has entered into an IP licence agreement with South Korea-based Asicland Co Ltd (KOSDAQ: 445090).

The deal gives ASICLAND non-exclusive, worldwide access to BrainChip's Akida neuromorphic AI technology. This allows ASICLAND to integrate Akida into its own system-on-chip designs for customers across multiple industries.

There is also a pathway from evaluation into full production.

ASICLAND can start with prototype and testing licences, then convert those into production licences if projects move forward.

BrainChip keeps ownership of its intellectual property and retains the option to work directly with end customers on additional services.

How the commercial model works

The structure follows a familiar model used across the semiconductor IP industry.

There are upfront fees for evaluation and production, along with ongoing royalties tied to chip sales. Extra service fees can also come into play depending on the level of support required.

Management said it's too early to put a figure on it, but expects the agreement to contribute revenue over time.

ASICLAND is positioned as both an enabler and a channel partner. It designs custom silicon solutions and works with customers across edge AI, industrial, automotive, and IoT markets.

Why investors are paying attention

Deals like this usually get attention because they show the tech is starting to move beyond development.

BrainChip has spent years developing its neuromorphic technology. What investors want to see now is evidence that it is being picked up and used in real products.

This agreement adds another partner to the ecosystem and creates more potential entry points into customer programs.

But while it does not guarantee near-term revenue, it does add more opportunities if these projects move forward.

Foolish Takeaway

This is another step forward for BrainChip, but there is still a significant gap between signing deals and seeing actual revenue.

Licensing agreements only start to matter once they move into production and generate ongoing royalties, which takes time and depends on customer uptake.

With this in mind, I would be watching from the sidelines until these partnerships come to fruition.

The post BrainChip shares rocket 6% on new chip deal appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is up 6.5% to 16.5 cents. This follows news that the struggling semiconductor company has signed an IP distribution license agreement. Brainchip has signed the deal with South Korean-based semiconductor solutions provider ASICLAND. The agreement sees BrainChip grant ASICLAND a non-exclusive, worldwide license to its Akida neuromorphic AI IP portfolio. However, the company advised that it "is unable to quantify the financial impact of the agreement at this time." ASICLAND reported revenue of approximately A$68.5 million for 2025, with a loss of A$25 million.

Minerals 260 Ltd (ASX: MI6)

The Minerals 260 share price is up 12% to 80.7 cents. This has been driven by the release of drilling results from the gold developer's Bullabulling Gold Project. Management notes that drilling continues to support strong potential for a resource upgrade at Bullabulling. Minerals 260's managing director, Luke McFadyen, said: "Drilling results since the December 2025 MRE continue to demonstrate the consistency and quality of the mineralisation at Bullabulling, with infill programs at Bacchus and Phoenix delivering strong results in line with, and in places exceeding, the current resource model."

Nuix Ltd (ASX: NXL)

The Nuix share price is up 4% to $1.55. This morning, this investigative and analytics software provider announced the appointment of a permanent CEO. Nuix revealed that its interim CEO, John Ruthven, has been selected after impressing during his tenure. Nuix's chair, Robert Mactier, said: "The Board has been impressed with the strategic, diligent and considered way John has embraced the role of Interim CEO and how he has resonated with our people and customers. The Board is unanimous in selecting John as our Chief Executive Officer and Managing Director, and we look forward to supporting him in driving the next phase of growth at Nuix."

Weebit Nano Ltd (ASX: WBT)

The Weebit Nano share price is up 8% to $4.48. This has been driven by the release of an announcement from the semiconductor company today. Weebit Nano advised that two product customers have successfully taped-out chip designs intended for eventual mass production which integrate its ReRAM module. One customer has a prototype already manufactured and functional. It notes that tape-out by product customers is an important milestone on the path to mass production. Weebit Nano's CEO, Coby Hanoch, said: "A first commercial product incorporating our ReRAM, and passing initial functional tests, is a significant achievement for Weebit Nano, marking an important step towards mass production. In addition, the tape-out by Overlord shows the great coordination between Overlord, DB HiTek and Weebit."

The post Why Brainchip, Minerals 260, Nuix, and Weebit Nano shares are racing higher today appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are tumbling:

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 3% to 15 cents. This follows the release of another disappointing update from the struggling semiconductor company. For the three months ended 31 March, Brainchip recorded customer cash inflows of US$700,000. However, this couldn't stop the company from recording an operating cash outflow of US$5.3 million for the three months. This led to its cash balance reducing to US$25.3 million from US$31.7 million.

Fortescue Ltd (ASX: FMG)

The Fortescue share price is down 5% to $19.93. For the third quarter of FY 2026, Fortescue reported total iron ore shipments of 48.4 million tonnes (Mt). This was below consensus estimates of approximately 49Mt, which may have disappointed investors. Fortescue Metals and Operations CEO, Dino Otranto, was pleased with the quarter. He said: "We delivered a solid quarter, contributing to record shipments of 148.7 million tonnes for the nine months to March. That reflects a significant effort from the team right across the business." Fortescue also separately announced that it has approved a US$680 million investment to expand its green energy capacity in the Pilbara.

IGO Ltd (ASX: IGO)

The IGO share price is down 15% to $7.28. This battery materials company's shares have been sold off following the release of its quarterly update. Although it posted a 45% increase in group sales revenue to $119.7 million, the market appears disappointed with an update on its guidance. IGO has updated full-year guidance for Greenbushes spodumene production to 1,375kt to 1,425kt (down from 1,500kt to 1,650kt). IGO's CEO, Ivan van Vella, said: "Fundamental changes to operating approaches and systems take time to be effective and improvements are typically not linear. Greenbushes is a world-class asset and generated 75% EBITDA margin this quarter. I am confident the work underway will deliver the required performance and overall value optimisation."

Life360 Inc (ASX: 360)

The Life360 share price is down 4% to $20.89. This follows another selloff of software stocks on Wall Street overnight. The catalyst for this may have been the release of GPT-5.5 by ChatGPT owner OpenAI. It stated: "We're releasing GPT‑5.5, our smartest and most intuitive to use model yet, and the next step toward a new way of getting work done on a computer."

The post Why Brainchip, Fortescue, IGO, and Life360 shares are tumbling today appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

4DMedical Ltd (ASX: 4DX)

The 4DMedical share price is down 10% to $5.63. This may have been driven by profit-taking from some investors following a very strong gain last week. Investors were buying the respiratory imaging technology company's shares after it made a big announcement. 4DMedical revealed that its CT:VQ technology has been deployed at the Mayo Clinic in the United States. The company's managing director and CEO, Andreas Fouras, commented: "Mayo's deployment is uniquely significant. When the world's number one hospital chooses to use your technology, it sends the strongest possible signal to the entire U.S. healthcare market about the clinical value and readiness of CT:VQ."

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 3.5% to 14 cents. Although this semiconductor company announced a licensing agreement today, the market doesn't appear overly impressed given the customer and the terms. BrainChip has entered into a technology licensing deal with Korea-based semiconductor company EDGEAI for its Akida 2 neuromorphic IP. The company will receive unspecified payments as it provides various deliverables, including IP access, engineering support, and integration services, as well as royalties on product sales. The agreement is global and non-exclusive, meaning EDGEAI is not restricted from working with other technology providers. In addition, it can be terminated by the customer without cause on one month's notice.

Catapult Sports Ltd (ASX: CAT)

The Catapult Sports share price is down 14% to $2.92. This follows the release of the sports technology company's analyst day presentation. Catapult revealed bold growth ambitions, targeting a rise in average annual contract value (ACV) per pro team from US$20,000 to between US$100,000 and US$150,000. However, this will depend on successful upselling to existing teams and launching additional products.

Star Entertainment Group Ltd (ASX: SGR)

The Star Entertainment share price is down 2% to 12.25 cents. This morning, this casino and resorts operator revealed that it has entered into a binding commitment letter with funds associated with WhiteHawk Capital Partners. This is in relation to a refinancing of its debt. It notes that the annual interest rate based on the term SOFR plus a margin that is materially consistent with its recent facility agreements.

The post Why 4DMedical, Brainchip, Catapult, and Star Entertainment shares are falling today appeared first on The Motley Fool Australia.

At the time of writing, the ASX tech stock is down 3.5% to 14 cents.

Why are Brainchip shares falling today?

The company's shares are falling today despite the release of an announcement revealing a long-awaited licensing agreement.

According to the release, BrainChip has entered into a technology licensing deal with Korea-based semiconductor company EDGEAI for its Akida 2 neuromorphic IP.

The agreement will see BrainChip provide access to its technology, along with integration support and development tools, to assist EDGEAI in incorporating Akida into its future products.

What is it worth?

The company hasn't been able to place a dollar figure on the estimated value of the agreement.

It notes the commercial structure of the agreement is tied to the delivery of technical milestones.

BrainChip will receive unspecified payments as it provides various deliverables, including IP access, engineering support, and integration services.

In addition, the company is eligible to receive royalties based on future product sales from EDGEAI that incorporate its technology. These royalties would only be payable once commercial shipments commence.

Furthermore, any potential royalty stream will be dependent on the success of EDGEAI's products in the market, which is a very large unknown. This is particularly the case given that EDGEAI isn't a proven name in the semiconductor industry.

In fact, rather embarrassingly, EDGEAI's website has gone offline today after exceeding its traffic quota.

Flexible terms

It is also worth highlighting that the agreement is global and non-exclusive, meaning EDGEAI is not restricted from working with other technology providers.

In addition, the licence remains in place only while EDGEAI continues to use the Akida IP and can be terminated by the customer without cause on one month's notice.

Brainchip's CEO, Sean Hehir, said:

We are excited to partner with EDGEAI as they bring their next generation AI solutions to market. This agreement reflects the growing global demand for neuromorphic computing and the unique advantages delivered by our Akida technology. Together, we are enabling smarter, more efficient edge devices that can operate with exceptionally low power while supporting sophisticated on device intelligence.

Foolish takeaway

While today's announcement represents progress in commercialising its technology, the financial contribution from the deal remains uncertain at this stage.

With milestone-based payments and royalties dependent on future product success, the extent to which this agreement translates into meaningful revenue will become clearer over time.

The post What's going on with BrainChip shares today? appeared first on The Motley Fool Australia.

This sees shares in the S&P/ASX 300 Index (ASX: XKO) artificial intelligence (AI) stock down about 43% over the past 12 months.

Nuix Ltd (ASX: NXL) shares have had an even tougher year.

Shares in the ASX 300 investigative analytics and intelligence software provider are down 1% at the time of writing, changing hands for $1.53 each. This puts the Nuix share price down 53.5% over 12 months.

For some context, the ASX 300 has gained 9.9% since this time last year.

And if Peak Asset Management's Niv Dagan has it right, Nuix and Brainchip shares could have further to fall (courtesy of The Bull).

Time to sell Brainchip shares?

"Brainchip is a commercial producer of neuromorphic artificial intelligence (AI)," said Dagan, who has a sell recommendation on Brainchip shares.

If you're not familiar with what that means, the company's neuromorphic processor, Akida, is intended to mimic the human brain and keep machine learning local to the chip, independent of the cloud.

"The company operates across Australia, the US and Europe and had a market capitalisation of about $349.17 million during trading on March 12," Dagan said.

Explaining his sell recommendation, Dagan said:

The broader AI hardware landscape is increasingly dominated by big players, such as Nvidia. The AI sector is intensively competitive. The company substantially lifted revenue in full year 2025 but reported a loss from continuing operations after tax.

Full-year revenue of US$1.9 million was up 374% from 2024. The loss from continuing operations came in at US$20.4 million.

"Brainchip shares have fallen from 24.5 cents on October 9, 2025, to trade at 14 cents on March 12. Other stocks appeal more at this stage of the cycle," Dagan concluded.

Also on the selling block

Apart from Brainchip shares, Dagan also recommends selling Nuix.

"Nuix is an investigative analytics software provider," he said. "It enables customers to process and search large data sets of unstructured information, including emails, documents and communications records."

Despite the sizeable one-year losses, Nuix shares are up 12.1% since the company reported its half-year results on 23 February.

Which could make today a good day to think about taking some profits, according to Dagan. He noted:

The company earns most of its revenue from licence and maintenance fees. Revenue of $121.2 million in the first half of fiscal year 2026 was up 15.2% on the prior corresponding period. Annualised contract value of $234.4 million was up 8.4%.

Investors may want to consider taking a profit as we believe gains are priced in following the half year result. We see limited scope for upside amid increasing competition.

The post Sell alert! Why this expert is calling time on Nuix and Brainchip shares appeared first on The Motley Fool Australia.

Well, if you are, let's see what analysts are saying about the popular shares in this article, courtesy of The Bull.

Are they buys, holds, or sells? Let's find out:

Brainchip Holdings Ltd (ASX: BRN)

The team at Peak Asset Management has named this struggling semiconductor company as a sell this week.

It highlights that the small cap is battling against AI giants like Nvidia (NASDAQ: NVDA) in an intensively competitive sector. It said:

BrainChip is a commercial producer of neuromorphic artificial intelligence (AI). The company operates across Australia, the US and Europe and had a market capitalisation of about $A349.17 million during trading on March 12. The broader AI hardware landscape is increasingly dominated by big players, such as Nvidia.

The AI sector is intensively competitive. The company substantially lifted revenue in full year 2025, but reported a loss from continuing operations after tax. The shares have fallen from 24.5 cents on October 9, 2025 to trade at 14 cents on March 12. Other stocks appeal more at this stage of the cycle.

CAR Group Limited (ASX: CAR)

Over at Baker Young, its analysts are positive on this auto listings company.

It highlights that its shares have fallen heavily recently amid AI disruption concerns. However, the broker believes this has created a buying opportunity and has named it as a buy this week. It said:

This online automotive marketplace operator posted stronger-than-expected first half results for 2026. It grew revenue by 13 per cent and reported EBITDA by 11 per cent. Recent sector-wide selling driven largely by concerns around potential artificial intelligence (AI) disruption has weighed on valuations. However, we believe CAR's trusted brands, established distribution network and strong dealer relationships position it well to integrate AI tools into its services rather than be disrupted by them.

Over time, AI could enhance listing quality, pricing transparency and advertising effectiveness across its platforms. Given the company's strong market position, attractive margins and long runway for digital automotive marketplace growth across several geographies, we view recent price weakness as an opportunity to accumulate a high quality technology-enabled marketplace at a more reasonable valuation.

Endeavour Group Ltd (ASX: EDV)

Finally, Baker Young has been looking at drinks giant Endeavour. It felt that the Dan Murphy's owner delivered a solid half-year result last month.

However, it isn't enough for a buy rating just yet. The broker has put a hold rating on its shares instead. It said:

The drinks and hotels operator delivered solid first half results for fiscal year 2026. Hotel sales increased by 4.4 per cent and total retail sales increased by 0.2 per cent. Hotel sales growth in the first seven weeks of the second half of fiscal year 2026 was up 4.5 per cent followed by 1.3 per cent for retail sales.

The company is investing heavily in price competition to support volumes, which will likely pressure margins in the near term. While it may be too early to call a full recovery, we believe risks are broadly balanced and we're comfortable maintaining our position ahead of the strategic update.

The post Buy, hold, sell: Brainchip, CAR Group, and Endeavour shares appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 9.5% to 14 cents. This struggling semiconductor company's shares have come under pressure again since the release of its full-year results last week. It was another disappointing release, with Brainchip reporting revenue of US$1.9 million and a massive operating loss of US$21.7 million for the 12 months. Investors appear to be doubting whether Brainchip will ever gain any meaningful commercial traction given how it is competing with companies that have R&D budgets that dwarf its own.

Fortescue Ltd (ASX: FMG)

The Fortescue share price is down 4% to $20.24. This has been driven by the iron ore giant's shares going ex-dividend this morning for its latest payout. Last month, Fortescue released its half-year results and reported a 23% increase in net profit after tax to US$1.9 billion. This allowed the Fortescue board to increase its fully franked interim dividend by 24% to 62 Australian cents per share. Eligible shareholders can now look forward to receiving this dividend later this month on 30 March.

Qantas Airways Ltd (ASX: QAN)

The Qantas share price is down 6% to $9.36. This appears to have been driven by war in the Middle East after the US struck Iran. And with Iran retaliating against its neighbours, this could impact travel demand in the near term. In addition, it is expected to cause oil prices to spike. And given how fuel is an airline's biggest operating cost, this could have a negative impact on its second-half earnings. A number of other ASX travel stocks are trading lower today in response to the news.

Westpac Banking Corp (ASX: WBC)

The Westpac share price is down 3% to $41.22. This is despite there being no news out of Australia's oldest bank. However, it is worth noting that all of the big four banks are trading lower today. This could have been driven by profit-taking from some investors after strong gains were recorded in the sector in February. This has seen the S&P/ASX 200 Financials index tumble by 2.7% on Monday afternoon.

The post Why Brainchip, Fortescue, Qantas, and Westpac shares are dropping today appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Bapcor Ltd (ASX: BAP)

The Bapcor share price is down 47% to 90.5 cents. This morning, the auto parts retailer's shares returned from a trading halt after completing the institutional component of its $200 million equity raising. The struggling retailer raised $157 million from institutional investors at a 65% discount of 60 cents per new share. The company's new CEO, Chris Wilesmith, said: "Raising $200M of equity will improve our financial flexibility and business resilience in the current market conditions and provide headroom to focus on 'getting the engine running' to improve our operating performance and execution." The retail component of the entitlement offer, which is fully underwritten, is expected to raise a further $43 million.

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 7% to 13 cents. Investors have been selling the embattled semiconductor company's shares after it released its full-year results. Brainchip reported revenue of US$1.9 million for the 12 months and a massive operating loss of US$21.7 million. Brainchip's founder and director, Peter van der Made, said: "We recognize that the ultimate measure of our strategy is commercial success. The foundations we continue to build in 2026 – from silicon validation to reference designs – are the essential drivers of our commercial success, and we are executing this strategy with full conviction. We remain deeply committed to the success of this Company and look forward to your continued engagement."

Coles Group Ltd (ASX: COL)

The Coles share price is down 9% to $20.20. This follows the release of the supermarket giant's half-year results. For the 27 weeks ended 4 January 2026, Coles reported a 2.5% lift in sales revenue to $23.6 billion and a 12.5% jump in profit after tax (excluding significant items) to $676 million. This was short of expectations. For example, Morgans was expecting a 3.5% increase in revenue and a 16.5% jump in underlying net profit after tax to $699 million.

Harvey Norman Holdings Ltd (ASX: HVN)

The Harvey Norman share price is down 8% to $5.81. This morning, this retail giant released its half-year results and reported a 6.9% increase in sales revenue to $5.16 billion and a 16.5% lift in profit after tax to $321.9 million. While this looks strong on paper, it was a touch short of consensus expectations.

The post Why Bapcor, Brainchip, Coles, and Harvey Norman shares are dropping today appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Bougainville Copper Ltd (ASX: BOC)

The Bougainville Copper share price is down 3.5% to 79 cents. Investors have been selling this copper stock after it announced the termination of a strategic partnering process with the president of the Autonomous Bougainville Government. This is in relation to the selection of an international mining partner for the redevelopment of the Panguna Mine.

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down a further 3.5% to 13.5 cents. This semiconductor company's shares have come under significant pressure since the release of another disappointing quarterly update. Brainchip reported cash receipts of just US$0.4 million for the three months ended 31 December, despite entering the commercialisation stage a few years ago. Investors appear to be doubting whether Brainchip realistically has any chance of ever competing with chip developers that spend billions on research and development each year.

Challenger Ltd (ASX: CGF)

The Challenger share price is down 3.5% to $8.60. This follows news that the annuities company is in advanced talks to jointly acquire Pepper Money Ltd (ASX: PPM) with Pepper Group ANZ HoldCo. Challenger believes the potential acquisition would provide long-term access to fixed income assets and support its strategic growth plans. If completed, Challenger would hold no more than 25% of total Pepper Money shares. It seems that the market isn't overly keen on the deal.

HMC Capital Ltd (ASX: HMC)

The HMC Capital share price is down almost 5% to $3.73. This morning, Morgan Stanley retained its equal-weight rating and $3.85 price target on the investment company's shares. Its analysts think that HMC Capital's shares are fair valued at current levels. Though, it is worth noting that other brokers see more value in the company's shares. For example, last month Morgans put a buy rating and $6.60 price target on its shares. Based on its current share price, this implies potential upside of approximately 75% for investors over the next 12 months. Time will tell which broker has made the right call on this one.

The post Why Bougainville Copper, Brainchip, Challenger, and HMC Capital shares are falling today appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 2% to 15.2 cents. This semiconductor company's shares have been under heavy selling pressure since the release of another disappointing quarterly update. Despite entering the commercialisation stage a few years ago, Brainchip revealed cash receipts of just US$0.4 million for the three months ended 31 December. Given that its market capitalisation is still $350 million, it wouldn't be surprising if the selling continues if there's no meaningful improvement in its sales.

Credit Corp Group Ltd (ASX: CCP)

The Credit Corp share price is down over 15% to $12.07. Investors have been selling this debt collector's shares following the release of its half-year results. Credit Corp posted a 4% increase in revenue to $283.6 million and flat net profit after tax of $44.1 million. Looking ahead, management believes it can still achieve its net profit after tax guidance range of $100 million to $110 million. Investors don't appear confident it will get there.

Graincorp Ltd (ASX: GNC)

The Graincorp share price is down 3% to $6.00. This may have been driven by a broker note out of Macquarie Group Ltd (ASX: MQG). This morning, the broker downgraded the grain exporter's shares to a neutral rating (from outperform) with a reduced price target of $6.60 (from $8.30). Macquarie appears concerned that margins could remain under pressure in the near term, which could weigh on its earnings growth.

Neuren Pharmaceuticals Ltd (ASX: NEU)

The Neuren Pharmaceuticals share price is down 12% to $14.25. This morning, Neuren Pharmaceuticals revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative trend vote on its marketing authorisation application for trofinetide in the European market. Neuren's CEO, Jon Pilcher, commented: "Given the totality of experience with trofinetide in clinical trials and real world use over many years, this negative trend vote is frustrating for us and the Rett syndrome community in the EU. We fully support Acadia's intention to seek re-examination of the CHMP opinion in February, if necessary."

The post Why Brainchip, Credit Corp, Graincorp, and Neuren shares are falling today appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 6% to 15.5 cents. Investors have been selling this semiconductor company's shares following the release of another disappointing quarterly update. Brainchip recorded cash receipts of just US$0.4 million for the three months ended 31 December. That's despite it entering the commercialisation stage a few years ago. And with its market capitalisation now at $350 million, it seems that some investors are finally recognising that this premium valuation is undeserved.

Galan Lithium Ltd (ASX: GLN)

The Galan Lithium share price is down 13% to 40.7 cents. This morning, this lithium developer announced that it has received firm commitments from institutional and sophisticated investors for a $40 million placement at a discount of 41 cents per new share. The proceeds will be used to complete phase one construction activities, expand phase one production capacity from 4 ktpa LCE to 5.2 ktpa LCE, undertake exploration activities at Greenbushes South, and for working capital purposes. The company's managing director, Juan Pablo Vargas de la Vega, commented: "An accelerated recovery in lithium prices has provided Galan with an opportunity to expand HMW Phase 1 production capacity by 30%."

Iluka Resources Ltd (ASX: ILU)

The Iluka Resources share price is down 13.5% to $5.58. Investors have been selling this mineral sands company's shares after it revealed that it would recognise $565 million in impairment charges in its upcoming first-half results. It advised: "The suspension [of the Cataby mine] was enacted given subdued demand for mineral sands and their associated downstream products, particularly pigment. The persistence of these demand conditions has impacted price expectations in the nearer term."

Ora Banda Mining Ltd (ASX: OBM)

The Ora Banda Mining share price is down 13% to $1.44. This morning, this gold miner released its quarterly update and revealed record gold production. However, looking further ahead, management is now guiding to the low end of its production guidance range and has increased its cost guidance meaningfully. Its FY 2026 all-in sustaining cost (AISC) is now expected to be $3,250 per ounce to $3,350 per ounce from $2,800 to $2,900 per ounce.

The post Why Brainchip, Galan Lithium, Iluka, and Ora Banda shares are tumbling today appeared first on The Motley Fool Australia.

In morning trade, the struggling semiconductor company's shares are down 3% to 16 cents.

This leaves them trading within a whisker of a multi-year low.

Why are Brainchip shares sinking?

Investors have been hitting the sell button again today after the company released yet another dismal quarterly update.

According to the release, the company recorded a cash inflow of just US$0.4 million for the three months ended 31 December.

That's an average of approximately US$130,000 a month for a company that entered the commercialisation stage a few years ago and has a market capitalisation over $360 million.

Unsurprisingly given its tiny cash inflows, Brainchip continues to burn cash. It revealed payments to suppliers and employees of US$4.3 million for the three months. Though, one small positive was that this was lower than the prior quarter when it spent US$5.2 million.

At the end of the quarter, the company had a cash balance of US$31.7 million. This is up from US$13.9 million in the prior quarter due to the successful completion of a US$22.8 million fully underwritten institutional placement in November.

Management notes that this capital raising was done to support the commercialisation of the Akida neuromorphic technology platform and the development of next-generation edge AI products. Though, time will tell if these funds accomplish anything other than paying the salaries of its leaders.

What else did it announce?

Brainchip also provided the market with an update on what it has been working on during the quarter.

This includes a strategic partnership with Blue Ridge Envisioneering, which is a Parsons (NYSE: PSN) entity. It notes that BRE is a Virginia-based innovator delivering next-generation solutions to the defence and intelligence sectors.

The terms of the agreement include an initial order of 10,000 chips, supporting the deployment of edge-AI systems that maintain full performance without cloud connectivity. It said:

Parsons will integrate BrainChip's Akida neuromorphic processors into its mission-ready platforms to enhance adaptive performance in constrained and dynamic defence environments. The agreed supply framework with Parsons includes committed volumes for manufacturing scale, continuity-of-supply provisions, and tiered pricing for high-volume deployment.

It also advised that it received an initial order for 1,200 AKD1500 chips from Nex Novus for use in its Neuromorphyx Neuro Blocks product. Management believes AKD1500 will accelerate an MCU supporting neuromorphic evaluation of multi-sensor data. And while it concedes that the order size is minor, it feels it represents further market demand for the AKD1500.

Time will tell if this leads to more orders, but I wouldn't hold my breath.

The post Why are Brainchip shares sinking today? appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Alliance Aviation Services Ltd (ASX: AQZ)

The Alliance Aviation Services share price is down 7% to $1.35. This appears to have been driven by a couple of broker notes out of Morgans and Ord Minnett. Both brokers have downgraded this aviation services company's shares to a hold rating from buy this morning. Morgans said: "AQZ has released a disappointing trading update with FY26 NPBT expected to be ~40% below our previous forecast and consensus. The stock is now in a very tough spot – ex-growth and earnings going backwards, management changes, accounting issues, highly levered balance sheet, poor cashflow generation and deteriorating returns on capital. With AQZ's strategic review ongoing, we are hopeful of possible corporate activity (but not guaranteed). Despite the poor earnings performance, the stock continues to trade well below NTA of ~A$2.90 and aviation assets are liquid and remain in strong demand. We downgrade our rating to HOLD."

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down almost 7% to 18.2 cents. This morning, this struggling semiconductor company announced a fully underwritten $35 million placement to professional and sophisticated investors. These funds are being raised at a 10.3% discount of 17.5 cents per new share. Brainchip's CEO, Sean Hehir, said: "This capital raise positions BrainChip to accelerate our leadership in edge AI and neuromorphic computing. With Akida 2.0 and our expanding product portfolio, we are unlocking new commercial opportunities in high-growth sectors and driving scalable innovation. Investor support enables us to execute with confidence and deliver long-term value through transformative, on-device intelligence."

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price is down almost 4% to $4.72. This has been driven by news that the pharmaceutical company has received a notice of intention to appeal by Cosette Pharmaceuticals. This relates to last month's judgement in the Supreme Court of New South Wales, which found in favour of Mayne Pharma and dismissed Cosette's request to cancel its takeover offer. Mayne Pharma notes that the notice of intention does not include any reasons for Cosette's intention to appeal.

Perpetual Credit Income Trust (ASX: PCI)

The Perpetual Credit Income Trust share price is down over 6% to $1.13. This has been driven by news that the income trust intends to raise up to ~$267 million via a 1 for 2 pro-rata non-renounceable entitlement offer to eligible unitholders and a shortfall offer. The proceeds are intended to be used to enable the investment manager to actively pursue additional investments in accordance with its current investment strategy and objective.

The post Why Alliance Aviation, Brainchip, Mayne Pharma, and Perpetual Credit shares are sinking today appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Australian Strategic Materials Ltd (ASX: ASM)

The Australian Strategic Materials share price is down 17% to $1.34. This morning, the integrated materials business revealed that it has received firm commitments for an institutional placement to raise approximately $55 million at a sizeable discount of $1.20 per new share. Managing director, Rowena Smith, said: "We are now fully funded to execute our Phase 2 ramp-up plan at the Korean Metals Plant (KMP). Completion of Phase 2 expansion activities will double our existing NdFeB alloy capacity to 3,600 tonnes per annum. This increased capacity will enable us to service the growing demand of our existing customers and the increasing number of enquiries we have received in recent months."

Bapcor Ltd (ASX: BAP)

The Bapcor share price is down 15% to $2.69. Investors have been selling this auto parts retailer's shares after it released its guidance for FY 2026. Management revealed that first half underlying profit is expected to be in the range of $14 million to $18 million. This is down sharply from $45.5 million in the prior corresponding period. On a statutory basis, things will be even worse, with a profit of $3 million to $7 million expected. And this doesn't include any potential impairments associated with the New Zealand segment. A stronger second half is expected, with management guiding to full year statutory profit in the range of $40 million to $50 million.

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 2.5% to 20.5 cents. This morning, this struggling semiconductor company appeared to change its business model out of the blue once again. After hyping up its potential to sell IP, Brainchip has now announced a shift back to trying to sell chips. This will see Brainchip tape out AKD1500 chip with its foundry partner. Though, the first units are not expected to be available until the third quarter of 2026. Brainchip CEO, Sean Hehir, said: "We are confident that this strategic step will position BrainChip for commercial success."

Deep Yellow Ltd (ASX: DYL)

The Deep Yellow share price is down 16% to $1.95. This has been driven by news that the uranium producer's CEO is stepping down after almost a decade at the company. Deep Yellow's chief financial officer (CFO), Craig Barnes, will lead the organisation as acting CEO until a permanent appointment is made. The company stated: "John leaves an incredible legacy at Deep Yellow having built one of the most experienced uranium mining leadership teams in the industry."

The post Why Australian Strategic Materials, Bapcor, Brainchip, and Deep Yellow shares are dropping today appeared first on The Motley Fool Australia.

But in reality, you don't need to chase risky stocks to build serious wealth on the ASX.

By taking a patient, disciplined approach, investors can let time and quality do most of the heavy lifting. Here's how.

Focus on quality ASX shares

The simplest way to double your portfolio is to own high-quality assets and give them time to grow. On the ASX, this can mean buying into reliable blue chips like Goodman Group (ASX: GMG) or global leaders such as ResMed Inc (ASX: RMD), which both have long track records of compounding returns.

Another approach is through exchange traded funds (ETFs). Funds like the iShares S&P 500 ETF (ASX: IVV) or the Betashares Nasdaq 100 ETF (ASX: NDQ) give you instant exposure to many of the world's best stocks, such as Microsoft (NASDAQ: MSFT) and Apple (NASDAQ: AAPL), without having to pick winners yourself.

The power of compounding

You don't need to double your money in one big leap. At a 10% average annual return, which is roughly in line with long-term equity market averages, your portfolio would double in just over 7 years.

That means $20,000 invested today could become $40,000 within a decade.

After which, as compounding accelerates your wealth creation, your ASX share portfolio would become worth $60,000 in approximately 12 years, $80,000 in approximately 15 years, and then $100,000 in approximately 17 years.

Reinvest dividends

One of the advantages of investing in Australia is the high dividend culture.

ASX shares like Telstra Group Ltd (ASX: TLS) and Harvey Norman Holdings Ltd (ASX: HVN) provide reliable, fully franked dividends that you can reinvest to supercharge compounding.

Over time, reinvested dividends can account for a good portion of total returns.

Avoid the traps

The temptation to chase speculative miners or unproven tech startups like Brainchip Holdings Ltd (ASX: BRN) can be strong, especially when markets are booming. But the risk of permanent capital loss is high.

By sticking to profitable businesses with competitive advantages and robust balance sheets, you reduce the chance of painful drawdowns that can set back your journey to doubling your portfolio.

Foolish takeaway

You don't need luck or risky punts to double your portfolio. What you need is time, discipline, and exposure to quality ASX shares and ETFs.

By focusing on businesses with strong fundamentals and reinvesting dividends along the way, you can steadily grow your wealth — and double your portfolio — without taking on unnecessary risk.

The post How to double your ASX share portfolio without chasing risky stocks appeared first on The Motley Fool Australia.